You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

275 Results
Guidelines and Advice
Apr 2019
Guidelines and Advice
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
May 2019
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2019
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Updated
Sep 2025
Guidelines and Advice
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Updated
Sep 2025

Pages